Get the latest news, insights, and market updates on NOTV (Inotiv, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, and VUGENE, a multi-omics data analysis company providing advanced artificial intelligence (AI) and machine learning (ML) solutions for biomedical research, today announced a strategic collaboration de Dec 11, 2025 - $NOTV
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million– Fiscal 2025 revenue increased 4.5% to $513.0 million– Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million– Fiscal 2025 operating loss decreased 64.2% to $30.9 million– Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discov Dec 3, 2025 - $NOTV
Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™
Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024WEST LAFAYETTE, Ind., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 182nd on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. Inotiv’s revenue grew 448% fr Nov 25, 2025 - $NOTV
Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025
WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended September 30, 2025, on Wednesday, December 3, 2025, after the close of the stock market. The Co Nov 21, 2025 - $NOTV
Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results
Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million Updated Time of Company Presentation at Jefferies Global Healthcare Conference WEST LAFAYETTE, Ind., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related pro Nov 17, 2025 - $NOTV
Inotiv, Inc. to Participate in Three Investor Conferences in November 2025
WEST LAFAYETTE, Ind., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming UBS Global Healthcare Conference, the Jefferies Glob Oct 21, 2025 - $NOTV
Inotiv, Inc. to Participate in Three Investor Conferences in September 2025
WEST LAFAYETTE, Ind., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming H.C. Wainwright 27th Annual Global Investment Confer Aug 13, 2025 - $NOTV
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple